Targeted Oncology Seed-stage biotech focused on an siRNA-based oncogene target and a novel nanoparticle delivery system, presenting an opportunity for collaboration, co-development, or licensing discussions with early-stage cancer programs and academic partnerships seeking innovative delivery modalities.

Delivery Innovation Novel nanoparticle delivery platform designed for both animals and humans, offering a potential sales angle for contract development, formulation services, or strategic partnerships with CROs and translational research labs seeking advanced delivery solutions.

Strategic Financing Current funding of five hundred thousand dollars and sub-million revenue signals readiness for pilot partnerships, grant collaborations, milestone-based licenses, or early-stage investment discussions to accelerate preclinical and translational milestones.

Founding Expertise Founders bring a century of combined academic and industry cancer R&D experience, providing credibility for co-development agreements, advisory roles, and introductions to potential collaborators, investors, and peer networks.

Market Positioning Operating in a highly competitive biotech landscape with large incumbents, PeptiMed can differentiate through focused oncology targets and delivery tech, suggesting opportunities for strategic alliances with mid-sized pharma, academic tech transfer offices, or grant-funded programs seeking differentiated early-stage assets.